AstraZeneca (NYSE:AZN) had its price objective raised by equities research analysts at Leerink Swann from $36.00 to $38.00 in a research note issued on Tuesday. The brokerage presently has a “market perform” rating on the stock. Leerink Swann’s price target indicates a potential upside of 10.79% from the stock’s current price.
Several other research firms have also issued reports on AZN. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Cowen reaffirmed a “hold” rating and issued a $37.00 price target on shares of AstraZeneca in a research note on Tuesday, October 17th. Sanford C. Bernstein raised their price target on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $35.20.
AstraZeneca (NYSE:AZN) traded up $0.52 during mid-day trading on Tuesday, hitting $34.30. 10,560,053 shares of the stock traded hands, compared to its average volume of 3,750,000. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. AstraZeneca has a twelve month low of $27.71 and a twelve month high of $36.70. The stock has a market cap of $88,710.00, a price-to-earnings ratio of 24.50, a P/E/G ratio of 2.78 and a beta of 0.74.
A number of institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its stake in AstraZeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after purchasing an additional 310,389 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in AstraZeneca by 103.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares in the last quarter. Zions Bancorporation lifted its stake in AstraZeneca by 2,719.4% in the 3rd quarter. Zions Bancorporation now owns 38,852 shares of the company’s stock worth $1,317,000 after purchasing an additional 37,474 shares in the last quarter. Wrapmanager Inc. lifted its stake in AstraZeneca by 21.1% in the 3rd quarter. Wrapmanager Inc. now owns 52,340 shares of the company’s stock worth $1,773,000 after purchasing an additional 9,120 shares in the last quarter. Finally, BB&T Investment Services Inc. lifted its stake in AstraZeneca by 54.9% in the 3rd quarter. BB&T Investment Services Inc. now owns 23,136 shares of the company’s stock worth $782,000 after purchasing an additional 8,199 shares in the last quarter. 14.79% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “AstraZeneca (AZN) Price Target Raised to $38.00 at Leerink Swann” was reported by American Market News and is owned by of American Market News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/06/astrazeneca-azn-price-target-raised-to-38-00-at-leerink-swann.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
